Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70-targeting CAR-T in advanced solid tumors
NCT05420545Phase 1Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD70 CAR-T cells in solid tumor, renal cell carcinoma (RCC), ovarian cancer and 1 more (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after CD70 CAR-T cells infusion at 28 days and Maximum Tolerated Dose of CD70 CAR-T cells at 28 days. Status: unknown.
02
Drugs
CD70 CAR-T cells
03
Conditions
solid tumorrenal cell carcinoma (RCC)ovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT05420545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420545.